Insider · CIK 0001821074

Jacobs Bruce N.

Reports to the SEC for 1 company · WATERTOWN, MA

sec.gov

Transactions

Companies

Filings

CIK

0001821074

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-30	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+61.4K sh	$5.33	+$327K	321,992
2026-06-30	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,500 sh	$110.54	−$166K	320,492
2026-06-30	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,700 sh	$111.57	−$190K	318,792
2026-06-30	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,100 sh	$112.79	−$124K	317,692
2026-06-30	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,110 sh	$114.19	−$469K	313,582
2026-06-30	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−51.4K sh	$114.77	−$5.9M	262,207
2026-06-30	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−7,971 sh	$115.82	−$923K	254,236
2026-06-30	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−6,153 sh	$116.99	−$720K	248,083
2026-06-30	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,200 sh	$117.70	−$377K	244,883
2026-06-30	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−61.4K sh	—	—	0
2026-06-02	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+12.7K sh	$2.08	+$26.3K	260,241
2026-06-02	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−12.7K sh	—	—	0
2026-05-18	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+15K sh	$2.08	+$31.2K	247,588
2026-05-18	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−15K sh	—	—	12,653
2026-03-04	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−492 sh	$84.00	−$41.3K	236,991
2026-03-04	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,519 sh	$85.04	−$214K	234,472
2026-03-04	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,437 sh	$85.78	−$123K	233,035
2026-03-04	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−447 sh	$86.62	−$38.7K	232,588
2026-03-02	KYMRKymera Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+17.7K sh	—	—	245,059
2026-03-02	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,039 sh	$87.75	−$179K	243,020
2026-03-02	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,424 sh	$88.50	−$126K	241,596
2026-03-02	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,113 sh	$89.66	−$369K	237,483
2026-03-02	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+35.3K sh	—	—	35,300
2025-09-17	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+79.2K sh	$2.08	+$165K	306,629
2025-09-17	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−79.2K sh	$50.00	−$3.96M	227,409
2025-09-17	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−42.2K sh	—	—	27,653
2025-09-17	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−37K sh	—	—	0
2025-03-31	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+25K sh	$2.08	+$52K	226,886
2025-03-31	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−25K sh	—	—	69,899
2025-03-03	KYMRKymera Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+30K sh	—	—	208,921
2025-03-03	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,754 sh	$30.33	−$175K	203,167
2025-03-03	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,281 sh	$31.00	−$39.7K	201,886
2025-03-03	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+60K sh	—	—	60,000
2025-01-10	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+10K sh	$2.08	+$20.8K	178,921
2025-01-10	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−10K sh	—	—	94,899
2024-06-27	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+25K sh	$2.08	+$52K	168,554
2024-06-27	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−25K sh	—	—	104,899
2024-03-04	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,378 sh	$41.41	−$98.5K	143,907
2024-03-04	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,301 sh	$42.39	−$55.2K	142,606
2024-03-04	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−255 sh	$43.26	−$11K	142,351
2024-03-01	KYMRKymera Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+31.3K sh	—	—	146,285
2024-03-01	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+188K sh	—	—	187,500
2023-06-02	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+10K sh	$2.08	+$20.8K	115,035
2023-06-02	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+10K sh	—	—	129,899
2023-03-02	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,056 sh	$30.88	−$32.6K	104,882
2023-03-02	KYMRKymera Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−314 sh	$31.40	−$9,858.752	104,568
2023-03-01	KYMRKymera Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+23.8K sh	—	—	105,938
2023-03-01	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+143K sh	—	—	142,500
2022-10-21	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+10K sh	$2.08	+$20.8K	81,279
2022-10-21	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−10K sh	—	—	139,899

Recent filings

Accepted (ET)
Jul 24
Jacobs Bruce N.0001193125-26-295090
SEC(opens sec.gov)
Jun 34
Jacobs Bruce N.0001193125-26-254589
SEC(opens sec.gov)
May 194
Jacobs Bruce N.0001193125-26-229656
SEC(opens sec.gov)
Mar 44
Jacobs Bruce N.0001193125-26-091982
SEC(opens sec.gov)

Companies

Kymera Therapeutics, Inc.Chief Financial OfficerKYMR

Address

C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, 4TH FLOOR

WATERTOWN, MA, 02472